Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Tim Wassenaar"'
Autor:
Arielle Baim, Jules H. Blank, Sandeep Saha, Harish Ahuja, Anne M. Traynor, Timothy S. Fenske, Ryan J. Mattison, Tim Wassenaar, Kyung Mann Kim, Namrata Shah, Patrick Mansky, Rubina Qamar, Chong Zhang, John P. Farnen, Brad S. Kahl, Adedayo A. Onitilo
Publikováno v:
Cancer. 121:3465-3471
BACKGROUND Proteasome inhibitors and mammalian target of rapamycin inhibitors each have activity in various B-cell malignancies and affect distinct cellular pathways. Their combination has demonstrated synergy in vitro and in mouse models. METHODS Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07fee0f189635ba243ef98770c1b74b4
https://doi.org/10.1002/cncr.29502
https://doi.org/10.1002/cncr.29502
Autor:
Walter L. Longo, Tim Wassenaar, Eliot C. Williams, J. Black, Brad S. Kahl, Deane F. Mosher, Bradford S. Schwartz
Publikováno v:
Hematological Oncology. 26:241-246
Bleeding diathesis and a hyper-fibrinolytic state often accompany a diagnosis of Acute Promyelocytic Leukaemia (APML). This complication can have grave effects if not successfully treated, with a 10-20% incidence of haemorrhagic death. We hypothesize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06a326b7f7a805d0fe75b951bba4cc2c
https://doi.org/10.1002/hon.867
https://doi.org/10.1002/hon.867
Autor:
Timothy S, Fenske, Namrata M, Shah, Kyung Mann, Kim, Sandeep, Saha, Chong, Zhang, Arielle E, Baim, John P, Farnen, Adedayo A, Onitilo, Jules H, Blank, Harish, Ahuja, Tim, Wassenaar, Rubina, Qamar, Patrick, Mansky, Anne M, Traynor, Ryan J, Mattison, Brad S, Kahl
Publikováno v:
Cancer. 121(19)
Proteasome inhibitors and mammalian target of rapamycin inhibitors each have activity in various B-cell malignancies and affect distinct cellular pathways. Their combination has demonstrated synergy in vitro and in mouse models.The authors conducted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::59488b09a25835caf47198bef605c525
https://pubmed.ncbi.nlm.nih.gov/26079295
https://pubmed.ncbi.nlm.nih.gov/26079295
Autor:
Rami S. Komrokji, Jessica K. Altman, Martin S. Tallman, Charles A. Schiffer, Zhuoxin Sun, Tim Wassenaar, Ryan J. Mattison, John M. Bennett, Jaroslaw P. Maciejewski, Selina M. Luger, Kathy L. McGraw, David F. Claxton, Puneet Cheema, Amit Verma, Lisa A Nardelli, Andrew S. Artz, Alan F. List
Publikováno v:
Blood. 128:223-223
Background: Treatment with rhu-Epo ameliorates anemia in a subset of LR-MDS patients, however, effective salvage therapy is limited. LEN promotes erythroid lineage competence and expansion of primitive erythroid precursors in vitro. In the MDS-002 an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::80373416fd10e526b9c4817f1ce6ab38
https://doi.org/10.1182/blood.v128.22.223.223
https://doi.org/10.1182/blood.v128.22.223.223
Autor:
Tim Wassenaar
Publikováno v:
The Hematologist. 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4835c45cdffa1e9882b2492a11f536ee
https://doi.org/10.1182/hem.v5.2.6378
https://doi.org/10.1182/hem.v5.2.6378
Autor:
Tim, Wassenaar, David, Feldstein
Publikováno v:
WMJ : official publication of the State Medical Society of Wisconsin. 104(6)
The well-done systematic review included a moderate number of patients from randomized controlled trials with an objective diagnosis of a brain tumor. There were mild differences between the 5 studies used in the systematic review with patients in 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cbdf60449a912152b040be2f904ab971
https://pubmed.ncbi.nlm.nih.gov/16218307
https://pubmed.ncbi.nlm.nih.gov/16218307
Autor:
Timothy S. Fenske, KyungMann Kim, Chong Zhang, John P. Farnen, Adedayo A. Onitilo, Jules H. Blank, Harish Ahuja, Tim Wassenaar, Rubina Qamar, Patrick Mansky, Anne Traynor, Ryan J. Mattison, Brad S. Kahl
Publikováno v:
Blood. 122:3035-3035
Background Proteosome inhibitors and mammalian target of rapamycin (mTOR) inhibitors are each known to have activity for various B-cell malignancies, and affect distinct cellular pathways. Preclinical data show synergy between bortezomib and various
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::220b5559b4b29ff1e3f59ad7dae44ac4
https://doi.org/10.1182/blood.v122.21.3035.3035
https://doi.org/10.1182/blood.v122.21.3035.3035
Autor:
Michael Volk, Julie E. Chang, Anne M. Traynor, Timothy S. Fenske, Matthias Weiss, Lynn M. Volk, Patrick Mansky, Chong Zhang, John P. Farnen, Michael A. Thompson, Jae Werndli, KyungMann Kim, Tim Wassenaar, Ali W. Bseiso, Rachel Kirby, Gerald Bayer, Craig E. Cole, Brad S. Kahl, Ronald S. Go, Jules H. Blank
Publikováno v:
Blood. 120:3647-3647
Abstract 3647 Introduction: BR chemoimmunotherapy was shown to have an overall response rate (ORR) of 59%, a median progression-free survival (PFS) of 14.7 months, and an acceptable toxicity profile in R/R CLL (Fischer K, et al. J Clin Oncol 2011). G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b268ac31ff880af0188a396cf022cef2
https://doi.org/10.1182/blood.v120.21.3647.3647
https://doi.org/10.1182/blood.v120.21.3647.3647